Kelly Elizabeth McCann MD PhD
Breast Cancer, Cancer Genetics/Cancer Risk Assessment
Assistant Clinical Professor
Join to View Full Profile
2336 Santa Monica Blvd., Suite 304Santa Monica, CA 90404
Phone+1 310-998-4747
Fax+1 310-998-4747
Dr. McCann is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
UCLA David Geffen School of Medicine/UCLA Medical CenterFellowship, Hematology and Medical Oncology, 2014 - 2017
Oregon Health & Science University (OHSU Health)Residency, Internal Medicine, 2011 - 2014
Stanford University School of MedicineClass of 2011, MD, PhD
Certifications & Licensure
OR State Medical License 2013 - Present
CA State Medical License 2014 - 2025
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Publications & Presentations
PubMed
- Goserelin 3-month depot shows non-inferiority to the monthly formulation in U.S. patients with premenopausal breast cancer: a real-world evidence study.Kelly E McCann, Noran Osman, Joan Cannon, Lonnie Brent, Yuexi Wang
Breast Cancer Research and Treatment. 2025-03-06 - 2 citationsClinical Significance of Background Parenchymal Enhancement in Breast Cancer Risk Stratification.Wakana Murakami, Shabnam Mortazavi, Tiffany Yu, Nikhita Kathuria-Prakash, Ran Yan
Journal of Magnetic Resonance Imaging. 2024-05-01 - 6 citationsSelection of appropriate biomarkers to monitor effectiveness of ovarian function suppression in pre-menopausal patients with ER+ breast cancer.Kelly E McCann, Shari B Goldfarb, Tiffany A Traina, Meredith M Regan, Neelima Vidula
NPJ Breast Cancer. 2024-01-19
Press Mentions
Surgical vs Neoadjuvant Therapy: A Lively Debate Among Experts Opens Miami Breast Cancer Conference 2025March 6th, 2025- TerSera® Presents New Real-World Evidence on Treatment Outcomes of Goserelin (ZOLADEX®) in Women with Breast Cancer at the 2024 San Antonio Breast Cancer SymposiumDecember 12th, 2024
- Why More Women Are Living with Stage 4 Breast CancerOctober 28th, 2023
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
